Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TAS2R8 | Q9NYW2 | 4/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | BRS3 | P32247 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772908 | 0.84 | IGF1R (0.41) | IGF1RHDAC1HDAC6TAS2R8AR | |
| SCHEMBL8016191 | 0.83 | AR (0.41) | HDAC1HDAC6TAS2R8ARHTR2A | |
| SCHEMBL8010256 | 0.82 | HDAC1 (0.41) | IGF1RHDAC1HDAC6TAS2R8FAAH | |
| SCHEMBL12873245 | 0.81 | HDAC1 (0.40) | IGF1RHDAC1HDAC6TAS2R8FAAH | |
| SCHEMBL8001609 | 0.80 | HDAC1 (0.45) | HDAC1HDAC6TAS2R8FAAHTNF | |
| SCHEMBL12873244 | 0.80 | HDAC1 (0.48) | HDAC1HDAC6TAS2R8FAAHTNF | |
| SCHEMBL8023329 | 0.79 | SLC6A4 (0.41) | HDAC1HDAC6TAS2R8FAAHHTR2A | |
| SCHEMBL8015498 | 0.79 | TAS2R8 (0.39) | IGF1RHDAC1HDAC6TAS2R8FAAH | |
| SCHEMBL8006342 | 0.79 | HDAC1 (0.38) | IGF1RHDAC1HDAC6TAS2R8FAAH | |
| SCHEMBL12873286 | 0.79 | AR (0.48) | IGF1RTAS2R8AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| EP-2252592-A1 | ARYLCHALCOGENO-ARYLALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009097998-A1 | ARYLCHALCOGENO-ARYLALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097998-A1 | ARYLCHALCOGENO-ARYLALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | PGC, LIPC, CEL | IGF1R 645/4885HDAC1 1393/4885HDAC6 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.